Shimizu et al., 2010 - Google Patents
siRNA-based therapy ameliorates glomerulonephritisShimizu et al., 2010
View HTML- Document ID
- 11411797793831462695
- Author
- Shimizu H
- Hori Y
- Kaname S
- Yamada K
- Nishiyama N
- Matsumoto S
- Miyata K
- Oba M
- Yamada A
- Kataoka K
- Fujita T
- Publication year
- Publication venue
- Journal of the American Society of Nephrology
External Links
Snippet
RNA interference by short interfering RNAs (siRNAs) holds promise as a therapeutic strategy, but use of siRNAs in vivo remains limited. Here, we developed a system to target delivery of siRNAs to glomeruli via poly (ethylene glycol)-poly (L-lysine)-based vehicles. The …
- 239000002924 silencing RNA 0 title abstract description 71
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Shimizu et al. | siRNA-based therapy ameliorates glomerulonephritis | |
| EP2415871B1 (en) | Polyion complex of double-stranded ribonucleic acid | |
| Suberi et al. | Polymer nanoparticles deliver mRNA to the lung for mucosal vaccination | |
| Zhang et al. | MicroRNA-125a-loaded polymeric nanoparticles alleviate systemic lupus erythematosus by restoring effector/regulatory T cells balance | |
| Judge et al. | Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice | |
| CN107531740B (en) | RNA nanoparticles for brain tumor treatment | |
| Whitehead et al. | Knocking down barriers: advances in siRNA delivery | |
| JP5872988B2 (en) | Composition that suppresses expression of target gene | |
| Yoon et al. | Self-assembled micelle interfering RNA for effective and safe targeting of dysregulated genes in pulmonary fibrosis | |
| KR101630888B1 (en) | Composition for suppressing expression of target gene | |
| KR102537540B1 (en) | Lipid nanoparticles comprising mannose or uses thereof | |
| EP3107549B1 (en) | Anionic polyplexes for use in the delivery of nucleic acids | |
| JP2021525508A (en) | Compositions and Methods of Adjustable Co-Coupling Polypeptide Nanoparticle Delivery Systems for Nucleic Acid Therapeutics | |
| Xiao et al. | Astrocyte-targeted siRNA delivery by adenosine-functionalized LNP in mouse TBI model | |
| Zhang et al. | Engineered ionizable lipid nanoparticles mediated efficient siRNA delivery to macrophages for anti-inflammatory treatment of acute liver injury | |
| Li et al. | Cholesterol‐Modified DNA Nanostructures Serve as Effective Non‐Viral Carriers for Delivering siRNA to the Kidneys to Prevent Acute Kidney Injury | |
| CN117241836A (en) | Composition for preventing or treating cancer comprising lipid nanoparticles | |
| CN111228505A (en) | Anthraquinone drug and nucleic acid compound nano delivery system and preparation method and application thereof | |
| JP5872898B2 (en) | Composition that suppresses expression of target gene | |
| JP5952197B2 (en) | Composition that suppresses expression of target gene | |
| Jain et al. | A novel method for producing functionalized vesicles that efficiently deliver oligonucleotides in vitro and in vivo in mice | |
| Mixson et al. | Targeting cancer with peptide RNAi nanoplexes | |
| EA046751B1 (en) | LIPID NANOPARTICLE FOR DELIVERY OF NUCLEIC ACID TO A PATIENT OR INTO A CELL | |
| CA3178609A1 (en) | Composition for preventing or treating obesity-related disease containing amphiregulin-specific double-stranded oligonucleotide structure | |
| CN117582511A (en) | Metal-phospholipid composite particles, and preparation method and application thereof |